CN102481249A - 包含相对构型-n-[6-[(2r，6s)-2，6-二甲基-4-吗啉基]-3-吡啶基]-2-甲基-4’-(三氟甲氧基)-[1，1’-联苯]-3-甲酰胺的局部药物组合物 - Google Patents

包含相对构型-n-[6-[(2r，6s)-2，6-二甲基-4-吗啉基]-3-吡啶基]-2-甲基-4’-(三氟甲氧基)-[1，1’-联苯]-3-甲酰胺的局部药物组合物 Download PDF

Info

Publication number
CN102481249A
CN102481249A CN2010800321676A CN201080032167A CN102481249A CN 102481249 A CN102481249 A CN 102481249A CN 2010800321676 A CN2010800321676 A CN 2010800321676A CN 201080032167 A CN201080032167 A CN 201080032167A CN 102481249 A CN102481249 A CN 102481249A
Authority
CN
China
Prior art keywords
compositions
choose
present
aforesaid right
right requires
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800321676A
Other languages
English (en)
Chinese (zh)
Inventor
A·弗里策
K·科尔塞勒
M·E·格鲁贝沙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN201410074829.6A priority Critical patent/CN103893184B/zh
Publication of CN102481249A publication Critical patent/CN102481249A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800321676A 2009-07-21 2010-07-20 包含相对构型-n-[6-[(2r，6s)-2，6-二甲基-4-吗啉基]-3-吡啶基]-2-甲基-4’-(三氟甲氧基)-[1，1’-联苯]-3-甲酰胺的局部药物组合物 Pending CN102481249A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410074829.6A CN103893184B (zh) 2009-07-21 2010-07-20 包含活性剂的局部药物组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22714109P 2009-07-21 2009-07-21
US61/227,141 2009-07-21
US29588410P 2010-01-18 2010-01-18
US61/295,884 2010-01-18
PCT/EP2010/060470 WO2011009852A2 (en) 2009-07-21 2010-07-20 Pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410074829.6A Division CN103893184B (zh) 2009-07-21 2010-07-20 包含活性剂的局部药物组合物

Publications (1)

Publication Number Publication Date
CN102481249A true CN102481249A (zh) 2012-05-30

Family

ID=42633096

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800321676A Pending CN102481249A (zh) 2009-07-21 2010-07-20 包含相对构型-n-[6-[(2r，6s)-2，6-二甲基-4-吗啉基]-3-吡啶基]-2-甲基-4’-(三氟甲氧基)-[1，1’-联苯]-3-甲酰胺的局部药物组合物
CN201410074829.6A Active CN103893184B (zh) 2009-07-21 2010-07-20 包含活性剂的局部药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410074829.6A Active CN103893184B (zh) 2009-07-21 2010-07-20 包含活性剂的局部药物组合物

Country Status (16)

Country Link
US (1) US8722672B2 (US07094801-20060822-C00139.png)
EP (1) EP2456422B1 (US07094801-20060822-C00139.png)
JP (2) JP6106434B2 (US07094801-20060822-C00139.png)
KR (1) KR101732751B1 (US07094801-20060822-C00139.png)
CN (2) CN102481249A (US07094801-20060822-C00139.png)
AR (1) AR077490A1 (US07094801-20060822-C00139.png)
AU (1) AU2010275240A1 (US07094801-20060822-C00139.png)
BR (1) BR112012001340B1 (US07094801-20060822-C00139.png)
CA (1) CA2768457C (US07094801-20060822-C00139.png)
ES (1) ES2576740T3 (US07094801-20060822-C00139.png)
HK (1) HK1199217A1 (US07094801-20060822-C00139.png)
IN (1) IN2012DN00239A (US07094801-20060822-C00139.png)
MX (1) MX2012000954A (US07094801-20060822-C00139.png)
RU (1) RU2589699C2 (US07094801-20060822-C00139.png)
TW (1) TW201107314A (US07094801-20060822-C00139.png)
WO (1) WO2011009852A2 (US07094801-20060822-C00139.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105330658A (zh) * 2015-12-09 2016-02-17 苏州明锐医药科技有限公司 索尼吉布的制备方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
KR20140026537A (ko) * 2011-06-02 2014-03-05 노파르티스 아게 헤지호그 억제제 요법을 위한 바이오마커
MX353017B (es) 2011-09-28 2017-12-18 Titan Wood Ltd Paneles de fibras de densidad media.
WO2014128661A1 (en) 2013-02-25 2014-08-28 Novartis Ag Oral formulation and suspension of an oncology drug
EP3279198B1 (en) * 2015-03-30 2020-01-01 Crystal Pharmatech Co., Ltd Crystal form of n-[6-(cis form-2,6-dimethylmorpholine-4-group)pyridine-3- group]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3- formamide monophosphate, and preparation method therefor
WO2016196928A1 (en) 2015-06-04 2016-12-08 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
CN112773805B (zh) * 2019-11-11 2024-05-10 中国科学院脑科学与智能技术卓越创新中心 缺血性脑损伤的新型治疗药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154259A1 (en) * 2007-06-07 2008-12-18 Irm Llc Biphenylcarboxamide derivatives as hedgehog pathway modulators
CN101445508A (zh) * 2008-11-21 2009-06-03 南京威尔化工有限公司 异山梨醇二甲醚的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
US5216011A (en) * 1989-09-01 1993-06-01 Bristol-Myers Squibb Co. Stable solutions of mitomycin c
IT1265001B1 (it) * 1993-12-16 1996-10-17 Zambon Spa Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
FR2719475B1 (fr) * 1994-05-05 1996-06-07 Oreal Composition cosmétique et/ou dermatologique à gélifiant polymérique cationique, ses utilisations notamment pour la dépigmentation de la peau.
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
RU2207124C1 (ru) * 2002-04-24 2003-06-27 Закрытое акционерное общество "Брынцалов-А" Крем "брамизил" противогрибкового действия
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
DE102006014454B3 (de) 2006-03-29 2007-11-08 Hoffmann, Frank Stanzvorrichtung mit Zuführeinrichtung
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154259A1 (en) * 2007-06-07 2008-12-18 Irm Llc Biphenylcarboxamide derivatives as hedgehog pathway modulators
CN101445508A (zh) * 2008-11-21 2009-06-03 南京威尔化工有限公司 异山梨醇二甲醚的合成方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
贾益群等主编: "《食品添加剂和药剂辅料质谱与红外光谱鉴定》", 31 December 2007, 吉林大学出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105330658A (zh) * 2015-12-09 2016-02-17 苏州明锐医药科技有限公司 索尼吉布的制备方法
CN105330658B (zh) * 2015-12-09 2017-09-19 苏州明锐医药科技有限公司 索尼吉布的制备方法

Also Published As

Publication number Publication date
US8722672B2 (en) 2014-05-13
JP6106434B2 (ja) 2017-03-29
JP2015199753A (ja) 2015-11-12
WO2011009852A2 (en) 2011-01-27
ES2576740T3 (es) 2016-07-11
RU2012105752A (ru) 2013-08-27
BR112012001340B1 (pt) 2021-08-03
CN103893184A (zh) 2014-07-02
HK1199217A1 (en) 2015-06-26
AR077490A1 (es) 2011-08-31
EP2456422B1 (en) 2016-03-16
CA2768457A1 (en) 2011-01-27
CN103893184B (zh) 2016-03-02
CA2768457C (en) 2018-01-23
RU2589699C2 (ru) 2016-07-10
BR112012001340A2 (pt) 2016-03-15
WO2011009852A3 (en) 2012-01-19
US20120122866A1 (en) 2012-05-17
AU2010275240A1 (en) 2012-02-02
KR101732751B1 (ko) 2017-05-04
KR20120097482A (ko) 2012-09-04
IN2012DN00239A (US07094801-20060822-C00139.png) 2015-05-01
MX2012000954A (es) 2012-02-28
JP2012533598A (ja) 2012-12-27
EP2456422A2 (en) 2012-05-30
TW201107314A (en) 2011-03-01

Similar Documents

Publication Publication Date Title
CN102481249A (zh) 包含相对构型-n-[6-[(2r，6s)-2，6-二甲基-4-吗啉基]-3-吡啶基]-2-甲基-4’-(三氟甲氧基)-[1，1’-联苯]-3-甲酰胺的局部药物组合物
KR102040479B1 (ko) Ｊａｋ 저해제에 대한 국소 제형
TWI650119B (zh) Ｇａｂａａ受體增強劑用於製備鎮靜麻醉藥物的用途
KR20120115380A (ko) 마이봄선 기능 장애의 치료 방법
KR102202481B1 (ko) 신규 용도
JP2012524814A (ja) １，２，４−チアジアゾール誘導体の安定的な局所組成物
JP7027437B2 (ja) ＲＯＲ－γモジュレーター
WO2018196662A1 (zh) 包含苯并二氮䓬类化合物的注射用组合物及其制备方法
JP2019519543A (ja) Ｐｄｅ−４阻害剤の局所処方物およびそれらの使用方法
EP1539155A1 (de) Stabile creme-zubereitungen von phenyl-pyridonverbindungen für topische anwendung
EP3061448B1 (en) Composition containing eugenol as active ingredient for preventing or treating atopic dermatitis
CN105792821A (zh) 包含1-茚满硫酰胺衍生物的疼痛治疗剂和/或预防剂
WO2015051763A1 (zh) 一种含埃克替尼的皮肤外用药物组合物及其应用
JP6625208B2 (ja) 経皮製剤
EP3666254A2 (en) Pharmaceutical composition containing (r)-n-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide
JP2013087067A (ja) ローション剤
WO2023016583A1 (zh) 一种芦可替尼组合物及其用途
WO2023076515A1 (en) Topical formulations of deucravacitinib
CA2156396A1 (en) Stable dermatologic preparation containing mycophenolic acid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120530